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Veronica Gomez, Talia Shackelford, Autumn Tocchi, Melissa Rowland-Goldsmith Ph.D. 
Abstract 
Pancreatic cancer is the fourth leading cause of cancer death in the United States. There have been several reports 
indicating that phytochemicals in fruits can reduce the risk of cancer due to the anti-oxidant and anti-inflammatory 
effects of the polyphenols. Our lab has shown that pomegranate juice extract (PJE) has anti-proliferative and pro-
apoptotic effects in human pancreatic cancer cells. In the past, we have shown that cells adhere more strongly to 
the plate when treated with PJE. This observation prompted an investigation of how PJE regulates cell adhesion 
proteins. Previously, our lab investigated E-cadherin, a cell adhesion protein. Upon activation of the Hedgehog 
signaling pathway, Gl-1 has been shown to down-regulate E-cadherin. The purpose of this study was to determine 
if PJE up-regulates ezrin, another cell adhesion protein, by interfering with the Gl-1 transcription factor of the 
Hedgehog signaling cascade. Through the use of immunoblots, we evaluated Gl-1 and ezrin protein levels after PJE 
treatment in COLO-357 human pancreatic cancer cells. We showed that pancreatic cancer cells treated with PJE 
led to decreased expression of Gl-1 and up-regulation of ezrin. This data suggests that PJE can help restore 
pancreatic cancer cell adhesion by blocking an important signaling pathway, thus serving as a potential suppressor 
of invasion and metastasis.  
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Introduction 
Pancreatic ductal adenocarcinoma is a devastating disease in which the overall five year survival rate is 
approximately 3-5% (1). Non-surgical treatment is generally ineffective due to the resistance of pancreatic cancer 
cells to chemotherapy and the tumor's ability to metastasize (1).  
The demand for dietary alternatives has prompted explorative studies on phytochemicals, which have been shown 
to be effective in fighting other cancers (2-13). Phenolic acids, flavanoids, and polyphenols are subgroups of 
phytochemicals, which are found in pomegranate juice extract (PJE) (12). Their ability to act as antioxidants makes 
them valuable agents in cancer therapies. Other studies have provided evidence for pomegranate juice extract's 
anti-inflammatory, antioxidant, chemotherapeutic, chemo-preventive, anti-proliferative, and pro-apoptotic 
properties (2-12). Recently, the complete pancreatic cancer genome sequence has been determined in which 12 
signaling pathways involved in promoting the disease were identified (14). 
One of these pathways is called the Hedgehog (HH) signaling pathway which has been found to be defective in 
patients with pancreatic cancer (15-17). Under normal circumstances, as seen in Fig. 1, the Hedgehog pathway 
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begins when the HH-protein binds to its receptor Patched (Ptc) (15). When HH is repressed the transmembrane 
protein Smoothened (Smo) is inhibited (15). When the HH protein binds to its receptor, Smo is activated and 
transduces a signal, thereby activating Gl-1 transcription factor. Gl-1 then translocates to the nucleus where it 
regulates gene transcription (15). In many cancers, this pathway is defective, causing an increase in HH protein and 
an over expression of the Gl-1 (15-17).  
 
In order for tumors to become metastatic, they must exhibit reduced cell-cell adhesion, alteration of tumor-
extracellular matrix interaction, and invasion of surrounding tissue (18). Low expression of E-cadherin correlates 
with increased pancreatic cancer proliferation and metastasis (19). Previous studies suggest that restoring these 
protein levels in pancreatic cancer cells promotes cell adhesion, leading to an increased rate in apoptosis (19). E-
cadherin and ezrin are two cell adhesion proteins that are involved in pancreatic cancer (16,19-22). In pancreatic 
cancer, E-cadherin is down-regulated by Gl-1 (16). Our laboratory has previously shown that PJE up-regulates E-
cadherin levels (data not shown). The present study was conducted to determine if pancreatic cancer cells treated 
with PJE up-regulates ezrin and whether it does so by interfering with the Gl-1 transcription factor. 
Methods 
Cell Culture: COLO-357 human pancreatic cancer cells (Dartmouth University) were grown in Dulbecco's Modified 
Eagle's (DME) complete media (CellGro) containing 10% fetal bovine serum (Irvine Scientific), 0.25 μg/ml 
fungazone (Omega Scientific), 100 μg/ml penicillin and 100 μg/ml streptomycin (Biowhitaker). Cells were 
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maintained in a humidified 5% CO2 and 95% air atmosphere at 37 degrees C. Confluent cells were removed from 
the plate using trypsin-EDTA (CellGro). 
Preparation of Cells for Experiments: Confluent cells were removed from the plate using trypsin-EDTA. 8x105 cells 
per well were seeded into 6 well plates and grown overnight in DME complete media. Plates were then grown 
overnight in DME serum free media containing 0.25 μg/ml fungazone, 100 μg/ml penicillin, 100 μg/ml 
streptomycin, and 1X ITS (insulin, transferrin, selenium) (Biowhitaker) before treatment. Cells were then treated 
with various concentrations of POM Wonderful PJE (48 hours) in triplicates: no treatment (NT), 10ug/ml PJE, 
25ug/ml PJE, and 50 ug/ml PJE.  
Immunoblotting: After incubation, protein lysates were collected and the protein concentrations were determined 
using a BCA assay (Thermo Scientific). The samples were run, along with a pre-stained BenchMark molecular 
weight marker (Invitrogen), on a 7.5% SDS-PAGE gel (BioRAD), electrotransferred to an Immobilin P membrane 
(Millipore), and blotted with a goat anti-rabbit ezrin (Santa Cruz) 1:500 dilution or goat anti-rabbit Gl-1 (Santa Cruz) 
1:200 dilution. Goat anti-rabbit ERK2 (Santa Cruz) was used at a 1:1,330 dilution as a loading control.  
Images: Images of immunoblots were taken using Fotodyne 60-0300 (Fotodyne Inc). Volumetric analysis was 
performed on images using the Total Lab Software (Nonlinear Dynamics Ltd).  
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Results
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There was a dose dependent decrease in Gl-1 when cells were treated with PJE (Figure 2). Ezrin protein levels had 
a dose dependent increase up to 25 μg/mL PJE treatment (Figure 3). There was an increase in the PJE treatment of 
50 μg/mL, however, it was weaker compared to the 25 μg/mL PJE treatment (Figure 3). 
Discussion 
We have shown in past research that the most prominent polyphenols in POM Wonderful PJE are Quinnic acid, 
Ellagic acid, Punicalin, and Punicalagin (data not shown). Ellagic acid has pro-apoptotic effects in pancreatic cancer 
(23). Formerly, we found that cancer cells treated with PJE led to decreased cell growth. This data partially explains 
why the cancer cells became more adherent to the culture dish. Since Ellagic acid is the only commercially 
available polyphenol found in pomegranates, we replicated the above experiments with this single polyphenol and 
found that the cancer cells also adhered more strongly to culture dishes and led to decreased cell growth, but to a 
much lesser degree than with PJE. This data suggests a need for the interaction between all polyphenols found in 
PJE. 
It is known that Gl-1 is over-expressed in most cancers (15-17). In our study, we showed that pancreatic cancer 
cells treated with PJE decreased Gl-1 expression, suggesting that PJE can inhibit the HH pathway. Based on the 
data, it is suggested that the polyphenols are interfering with the HH pathway by down regulating the Gl-1 
transcription factors. Since transcription of E-cadherin is inversely dependent on the Gl-1 transcription factor, the 
decrease in the Gl-1 expression increases the E-cadherin expression (16). While there is no published data to 
support that ezrin is directly regulated by Gl-1, the similarities between E-cadherin and ezrin could suggest a 
similar interaction between Gl-1 and ezrin in the HH signaling pathway. This relation is due to the fact that both are 
cell adhesion proteins and both have been shown to be involved in pancreatic cancer (19-22). We have 
demonstrated that both adhesion proteins have an increased expression when pancreatic cells were treated with 
PJE. 
Our data contradicts the current studies on ezrin expression, including pancreatic cancer. In these studies, a high 
expression of ezrin correlates with a poor outcome (20-22). Specifically, ezrin leads to an increase in the spread of 
the cancer through its interaction with signaling events that are involved in the regulation of cell survival, 
proliferation, and migration (20-22). Like our data, a few studies have shown that weak ezrin expression correlates 
with poor patient outcome (24,25). Instead of pancreatic cancer, however, these studies examined serous ovarian 
carcinoma and lung adenocarcinoma (24,25). Our findings are the first to show that increased expression of ezrin 
leads to an inhibition of pancreatic cancer growth. Based on this study, we suggest that ezrin is regulated by the 
HH signaling pathway, similar to E-cadherin. When Gl-1 levels are low, ezrin levels are high. In conclusion, this 
study suggests that PJE has possible benefits for pancreatic cancer. However, our experiments need to have 
increased replication to confirm these novel results.  
Acknowledgments 
This project would not have been possible without the generous donation of the COLO-357 pancreatic cancer cell 
line from Dartmouth University, Chapman University's undergraduate student research grant and Faculty Research 
Grant. 
References 
1.       Welsch T.; Kleeff, J. and Friess H. Molecular Pathogenesis of pancreatic cancer: advances and challenges. Curr 
Mol Med. 2007, 7 (5), 504-521. 
6
e-Research: A Journal of Undergraduate Work, Vol. 1, No. 2 [2014], Art. 7
http://digitalcommons.chapman.edu/e-Research/vol1/iss2/7
  The Effect of Pomegranate Juice 
e-Research, Vol 1, No 2 (2010)   99 
 
2.       Syed D.N.; Afaq F.; Mukhtar H. Pomegranate Derived products for Cancer Chemoprevention. Seminars in 
Cancer Bio. 2007, 17, 377-385. 
3.       Malik A., Afaq F. Sarfaraz S., Adhami VM, Syed DN, Mukhtar H. Pomegranate fruit juice for chemoprevention 
and chemotherapy of prostate cancer. Proc Natl Acad Sci. USA 2005; 102 (41):14813-8. 
4.       Sartippour MR, Seeram NP, Rao JY, Moro A, Harris DM, Henning SM, Firouzi A, Rettig MB, Aronson WJ, 
Pantuck AJ, Heber D. Ellagitannin-rich pomegranate extract inhibits angiogensis in prostate cancer in vitro and in 
vivo. Int. J. Oncol. 2008. 32, (2), 475-480. 
5.       Adams, L. S.; Seeram, N. P.; Aggarwal, B. B.; Takada, Y.; Sand, D.; Heber, D., Pomegranate juice, total 
pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. Journal of 
Agricultural and Food Chemistry 2006, 54, (3), 980-985. 
6.       Khan, N.; Hadi, N.; Afaq, F.; Syed, D. N.; Mee-Hyang, K.; Mukhtar, H., Pomegranate fruit extract inhibits 
prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice. Carcinogenesis 
2007, 28, (1), 163-173. 
7.       Jeune M. A.; Kumi-Diaka J.; Brown,J., Anticancer activities of pomegranate extracts and genistein in human 
breast cancer cells. Journal of Medicinal Food 2005, 8, (4), 469-475. 
8.       Kim ND, Mehta R, Yu W, Neeman I, Livney T, Amichay A, Poirier D, Nicholls P, Kirby A, Jiang W. 
Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. 
Breast Cancer Research Treatment. 2002, 71:203-216. 
9.       Toi M, Bando H, Ramachandran C, Melnick SJ, Imai A, Fife RS, Carr RE, Oikawa T, Lansky EP. Preliminary 
studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. Angiogenesis, 2003,6: 121-8 
10.    Seeram NP, Adams LA, Henning SM, Niu Y, Zhang Y, Nair MG, Heber D. In vitro antiproliferative, apoptotic, and 
antioxidant activities of puicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in 
combination with other polyphenols as found in pomegranate juice. J. Nutr Biochem 2005; 16:360-367. 
11.    Yang CS, Landau JM, Huang MT, Newmark HC. Inhibition of carcinogenesis by dietary polyphenolic 
compounds. Annu Rev Nutr. 2001, 21, 381-406. 
12.    Afaq F, Saleem M, Krueger CG, Reed JD, Mukhtar H. Anthocyanin and hydrolysable tannin-rich pomegranate 
fruit extract modulates MAPK and NF-kappa B pathways and inhibits skin tumorigenesis in CD-1 mice. Int J Cancer. 
2005,113, 423-33. 
13.    Slusarz, A., Shenouda, N.S., sakla, M.S., Drenkhahn, S.K., Narula, A.S., MacDonald, R.S., Besch-Williford, C.L., 
Lubahn, D.B. Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer 
Research. 2010. 70:3382-90. 
14.    Jones S.; Zhang X., Parsons D.W., Lin J. C-H; Leary R.J.; Angenendt P.; Mankoo P.; Carter H.; Kamiyama H.; 
Jimeno A.; Hong S-M; Fu B.; Lin M-T; Calhoun E.S.; Kamiyama M.; Walter K.; Nikolskaya T.; Nikolsky Y.; Hartigan J.; 
Smith D.R.; Hidalgo M.; Leach S.D.; Klein A.P.; Jaffee E.M.; Goggins M.; Maitra A.; Iacobuzio-Donahue C.; Eshleman 
J.R.; Kern S.E.; Hruban R.H.; Karchin R.; Papadopoulos N.; Parmigiani G.; Vogelstein B.; Velculescu V.E.; Kinzler K.W. 
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses Science. 2008, 
321(5897), 1801-6.  
7
Gomez et al.: The effect of pomegranate juice extract on the Hedgehog signaling
Published by Chapman University Digital Commons, 2014
V. Gomez, T. Shackelford, A. Tocchi, M. Rowland-Goldsmith 
100   e-Research, Vol 1, No 2 (2010) 
 
15.    Kasper, M., Regl, G., Frischauf, A-M., Aberger, F. GLI transcription factors: Mediators of oncogenic Hedgehog 
signaling. European Journal of Cancer. 2006. 42:437-445. 
16.    Feldmann, G., Dhara, S., Fendrich, V., Bedja, D., Beaty, R., Mullendore, M., Karikari, C., Alvarez, H., Iacobuzio-
Donahue, C., Jimeno, A., Gabrielson, K. L., Matsui, W., and Maitra, A. Blockage of Hedgehog Signaling Inhibits 
Pancreatic Cancer Invasion and Metastases: A New Paradigm for combination Therapy in Solid Cancers. Cancer 
Research. 2007. 67:2187-2196 
17.    Nolan-Stevaux, O., Lau, J., Truitt, M. L., Chu, G. C., Hebrok, M., Fernandez-Zapico, M. E., Hanahan, D. Gli1 is 
regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell 
survival and transformation. Genes and Development. 2009.23:24-36 
18.    Keleg S.; Buchler P.; Ludwig R.; Buchler M.; Friess H. Invasion and Metastasis in pancreatic cancer. Molec 
Cancer. 2003, 2(14), 1-7. 
19.    Lowry A.M.; Knight J.; Groden J. Restoration of E-cadherin/beta-catenin expression in pancreatic cancer cells 
inhibits growth by induction of apoptosis. Surgery. 2002, 132(2), 141-8. 
20.    Tsukita S, Yonemura S, Tsukita S. ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. 
Current Opinion in Cell Biology. 1997.9:70-75. 
21.    Akisawa N, Nishimori I, Iwamura T, Onishi S, Hollingsworth M. 1999. High levels of ezrin expressed by human 
pancreatic adenocarcinoma cell lines with high metastatic potential. Biochemical and Biophysical Research 
Communications. 258: 395-400. 
22.    Cui Y, Li T, Zhang D, Han J. Expression of Ezrin and phosphorylated Ezrin (pEzrin) in pancreatic ductal 
adenocarcinoma. Cancer Invest. 2010. 28(3):242-7. 
23.    Edderkaoui, M., Odinokova, I., Ohno, I., Gukovsky, I., Liang, V., Go, W., Pandol, S.J., Gukovskaya, A.S. Ellagic 
acid induces apoptosis through inhibition of nuclear factor ΚB in pancreatic cancer cells. World Journal of 
Gastroenterology. 2008. 14:3672-3680. 
24.    Moilanen, J., Lassus, H., Leminen, A., Vaheri, A., Butzow, F., and Carpen, O. Ezrin immunoreactivity in relation 
to survival in serous ovarian carcinoma patients. Gynecologic Oncology. 2003. 90:273-281 
25.    Tokunou, M., Niki, T., Saitoh, Y., Imamura, H., Sakamoto, M., Hirohashi, S. Altered Expression of the ERM 
Proteins in Lung Adenocarcinoma. Laboratory Investigation. 2000. 80:1643-1650. 
8
e-Research: A Journal of Undergraduate Work, Vol. 1, No. 2 [2014], Art. 7
http://digitalcommons.chapman.edu/e-Research/vol1/iss2/7
